CAND2 Gene (Cullin-Associated and Neddylation-Dissociated 2)
A key regulator of cullin-RING ubiquitin ligase (CRL) assembly and activity, involved in cell cycle control and tumorigenesis.
Gene Information Card
| Symbol | CAND2 |
|---|---|
| Full Name | Cullin-Associated and Neddylation-Dissociated 2 |
| Gene Type | Protein coding |
| Chromosomal Location | 3p24.3 |
| NCBI Gene ID | 23066 ncbi.nlm.nih.gov/gene/23066 |
| Ensembl ID | ENSG00000144713 |
| UniProt ID | Q9H6Q4 |
| OMIM ID | 611745 |
| HGNC ID | 30689 |
| Aliases | TIP120B, TIP120B, CAND2, FLJ10324 |
Description
CAND2 (cullin-associated and neddylation-dissociated 2) encodes a protein that binds to cullin-RING ubiquitin ligase (CRL) complexes, inhibiting their activity by preventing neddylation and substrate recruitment. It plays a role in cell cycle progression, DNA damage response, and is implicated in various cancers. The gene is located on chromosome 3p24.3 and is expressed in multiple tissues.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | CAND2 overexpression may disrupt CRL-mediated degradation of cell cycle regulators, promoting proliferation. | COSMIC; PMID: 25691885 |
| Colorectal cancer | Mutations in CAND2 have been identified in tumor samples, potentially altering CRL assembly and contributing to genomic instability. | COSMIC; PMID: 26691986 |
| Lung cancer | Altered CAND2 expression correlates with poor prognosis; functional studies suggest role in modulating p53 pathway via CRL. | ClinVar; PMID: 28270531 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Brain | 8.3 | Low |
| Lung | 6.1 | Low |
| Liver | 4.7 | Low |
| Kidney | 5.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK293 | 10.2 | Embryonic kidney cell line |
| HeLa | 8.9 | Cervical cancer cell line |
| A549 | 7.4 | Lung carcinoma cell line |
| MCF7 | 6.8 | Breast cancer cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1234C>T (p.Arg412*) | Nonsense | 0.02% (COSMIC) | Loss of function; truncated protein unable to bind cullins |
| c.567G>A (p.Gly189Arg) | Missense | 0.01% (ClinVar) | Unknown; predicted damaging by SIFT |
| c.2101_2102insA | Frameshift | 0.005% (COSMIC) | Loss of function; premature stop codon |
Mutation functional classification
Loss of Function (LOF)
Nonsense and frameshift mutations lead to truncated CAND2 protein, impairing its ability to regulate CRL neddylation and substrate degradation.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in curated databases.
Dominant Negative (DN)
Missense mutations in the cullin-binding domain may produce a dominant-negative effect by sequestering cullins without functional regulation.
View complete mutation data：
Gene Ontology (GO)
Pathways
• hsa04120: Ubiquitin mediated proteolysis
• hsa04110: Cell cycle
• hsa05200: Pathways in cancer
Protein Summary
The CAND2 protein (UniProt Q9H6Q4) is a 120 kDa protein that contains a conserved cullin-binding domain. It binds to unneddylated cullins, preventing their association with the E2 ubiquitin-conjugating enzyme and thereby inhibiting CRL activity. This regulation is critical for proper cell cycle progression and DNA repair. CAND2 is widely expressed, with highest levels in testis. Mutations in CAND2 are associated with loss of function in cancer, and its expression is altered in several tumor types.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CAND2 Knockout HEK293 Cell Line | EDJ-KQ7806 | Human | 23066 | Details Get a Quote |
| CAND2 Knockout A-549 Cell Line | EDJ-KQ33325 | Human | 23066 | Details Get a Quote |
| CAND2 Knockout HeLa Cell Line | EDJ-KQ55682 | Human | 23066 | Details Get a Quote |
| CAND2 Knockout HCT 116 Cell Line | EDJ-KQ72623 | Human | 23066 | Details Get a Quote |
